EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Primary objective: to assess the efficacy of Bacillus clausii versus metronidazole in the
eradication of the small intestinal bacterial overgrowth, 30 days after the end of treatment.
Secondary objective: to assess the efficacy of Bacillus clausii versus metronidazole in
avoiding recurrence of the small intestinal bacterial overgrowth, 90 days after the end of
the treatment; to assess the efficacy of Bacillus clausiiversus metronidazole in improving
irritable bowel syndrome -related symptoms; to assess the efficacy of Bacillus clausii versus
metronidazole in the satisfactory relief of overall irritable bowel syndrome symptoms and of
abdominal discomfort or pain; to assess the efficacy of Bacillus clausii versus metronidazole
in improving irritable bowel syndrome quality of life.